
|Videos|July 2, 2013
Episode 13 - Treatment Challenges for Progressive Disease
Advertisement
Episodes in this series

Because there aren’t treatment options available for the management of progressive multiple sclerosis (MS), Patricia K. Coyle, MD, explains the challenges clinicians are faced with when treating patients who transition into a progressive stage of the disease.
Dr Coyle and Leslie Fish, PharmD, explain that although the topic of when to end therapy for patients who transition into a worsening stage is controversial, it is necessary to make personalized treatment decisions.
Dr Fish further explains how the rising costs of agents for the treatment MS further complicate management of MS and affect a clinician’s decision about when to begin or end therapy for a patient.
Advertisement
Related to this article

In this Q&A, Konstantin Dmitrievich Penkov, MD, discusses delayed quality-of-life decline with cemiplimab plus chemotherapy in aNSCLC.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."
Advertisement
Advertisement
Trending on AJMC
1
Value-Based Pilot for Medicaid Members With Substance Use Disorder
2
Acne Treatment Adherence Ranges From 6% to 84% in Real-World Studies
3
Real-World Brexu-cel Results in MCL Mirror Trials; Cost, QOL Data Lag
4
Four Ways to Boost Awareness, Access for COVID-19 PEP
5

















